Previous Section
Clinical Trials
1. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500).
- Author
- Petersdorf SH; Rankin C; Head DR; Terebelo HR; Willman CL; Balcerzak SP; Karnad AB; Dakhil SR; Appelbaum FR;
- Institution
- Division of Medical Oncology, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Puget Sound Oncology Consortium, Seattle, Washington 98109, USA. spetersd@u.washington.edu
- Journal
- Am J Hematol. 2007 Dec;82(12):1056-62.
- Abstract URL
- Click here to view abstract
2. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
- Author
- Vehreschild JJ; Bohme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA;
- Institution
- Klinikum der Universitat zu Koln, Klinik I fur Innere Medizin, Studienzentrum Infektiologie II, 50937 Koln, Germany.
- Journal
- J Infect. 2007 Nov;55(5):445-9. Epub 2007 Sep 6.
- Abstract URL
- Click here to view abstract
3. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
- Author
- Pollyea DA; Artz AS; Stock W; Daugherty C; Godley L; Odenike OM; Rich E; Smith SM; Zimmerman T; Zhang Y; Huo D; Larson R; van Besien K;
- Institution
- Department of Internal Medicine, University of Chicago Hospitals, Chicago, IL 60637, USA.
- Journal
- Bone Marrow Transplant. 2007 Dec;40(11):1027-32. Epub 2007 Sep 10.
- Abstract URL
- Click here to view abstract
4. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.
- Author
- Sorror ML; Giralt S; Sandmaier BM; De Lima M; Shahjahan M; Maloney DG; Deeg HJ; Appelbaum FR; Storer B; Storb R;
- Institution
- Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA 98109-1024, USA. msorror@fhcrc.org
- Journal
- Blood. 2007 Dec 15;110(13):4606-13. Epub 2007 Sep 14.
- Abstract URL
- Click here to view abstract
5. Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.
- Author
- Fianchi L; Pagano L; Leoni F; Storti S; Voso MT; Valentini CG; Rutella S; Scardocci A; Caira M; Gianfaldoni G; Leone G;
- Institution
- Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Roma, Italy. luana.fianchi@rm.unicatt.it
- Journal
- Ann Oncol. 2008 Jan;19(1):128-34. Epub 2007 Sep 28.
- Abstract URL
- Click here to view abstract
6. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older.
- Author
- Eom KS; Kim HJ; Min WS; Lee S; Min CK; Cho BS; Kim SY; Kim YJ; Lee DG; Choi SM; Cho SG; Kim DW; Lee JW; Shin WS; Kim CC;
- Institution
- Catholic Hematopoietic Stem Cell Transplantation Center, St Mary's Hospital, The Catholic University of Korea, Seoul, Korea. dreom@catholic.ac.kr
- Journal
- Eur J Haematol. 2007 Nov;79(5):398-404. Epub 2007 Oct 4.
- Abstract URL
- Click here to view abstract
7. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.
- Author
- Pieters R; Schrappe M; De Lorenzo P; Hann I; De Rossi G; Felice M; Hovi L; LeBlanc T; Szczepanski T; Ferster A; Janka G; Rubnitz J; Silverman L; Stary J; Campbell M; Li CK; Mann G; Suppiah R; Biondi A; Vora A; Valsecchi MG;
- Institution
- Dutch Childhood Oncology Group (DCOG, Netherlands) Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands. rob.pieters@erasmusmc.nl
- Journal
- Lancet. 2007 Jul 21;370(9583):240-50.
- Abstract URL
- Click here to view abstract
8. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
- Author
- Karp JE; Giles FJ; Gojo I; Morris L; Greer J; Johnson B; Thein M; Sznol M; Low J;
- Institution
- Leukemia Program, Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231-1000, USA. jkarp2@jhmi.edu
- Journal
- Leuk Res. 2008 Jan;32(1):71-7. Epub 2007 Jul 20.
- Abstract URL
- Click here to view abstract
9. Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.
- Author
- Gutierrez-Aguirre CH; Cantu-Rodriguez OG; Gonzalez-Llano O; Salazar-Riojas R; Martinez-Gonzalez O; Jaime-Perez JC; Morales-Toquero A; Tarin-Arzaga LC; Ruiz-Arguelles GJ; Gomez-Almaguer D;
- Institution
- Servicio de Hematologia del Hospital Universitario Dr Jose E. Gonzalez, Universidad Autonoma de Nuevo Leon, Monterrey, NL, Mexico.
- Journal
- Hematology. 2007 Jun;12(3):193-7.
- Abstract URL
- Click here to view abstract
10. Autologous bone marrow transplantation for children with AML in first remission.
- Author
- Neudorf S; Sanders J; Kobrinsky N; Alonzo TA; Buxton A; Buckley JD; Howells W; Gold S; Barnard DR; DeSwarte J; Kalousek D; Lange BJ; Woods WG;
- Institution
- Children's Hospital of Orange County, 455 S. Main Street, Orange, CA 92868, USA. sneudorf@choc.org
- Journal
- Bone Marrow Transplant. 2007 Aug;40(4):313-8. Epub 2007 Jun 11.
- Abstract URL
- Click here to view abstract
